The Nature and the Extent of the Market for Technology in Biopharmaceuticals
The biopharmaceutical industry is a typical example of the development of technological collaborations, as well as of technological competition, between larger established firms and smaller high-tech specialist firms (the so-called New Biotechnology Firms — NBFs). These two types of firms perform innovative activities at different stages, with different degree of risk, and with different probability of failure. By using a comprehensive database of 2078 drug R&D projects promoted all over the world during the 1990s, this study assesses the different performance of R&D processes conducted under different governance structures, most notably projects that are fully internalised by the companies vis-àvis projects developed in collaboration with other firms. Moreover, this study compares the different specialisation and performance of large drug companies with respect to the NBFs. Results show that the established pharmaceutical companies have comparative advantages with respect to NBFs in drug development, while there is no advantage related to scale in drug discovery. Furthermore, NBFs undertake less risky project, which are more likely to fail at earlier clinical stages.
KeywordsResearch collaborations R&D Management Pharmaceutical Industry Biotechnology
Unable to display preview. Download preview PDF.
- Arora, A., Fosfuri, A. and Gambardella, A. (2000) Markets for Technology: Why Do We See Them, Why Don’t We See More of Them, and Why Should We Care, manuscript, Carnegie Mellon University, Pittsburgh.Google Scholar
- Arrow K.J., 1983, “Innovation in Large and Small Firms”, in Ronen J. (ed.) Entrepreneurship, Lexington Books, Lexington, Ma.Google Scholar
- Gans, J., Hsu, D. and Stern, S. (2000) “When Does Start-Up Innovation Spur the Gale of Creative Destruction?” NBER Working Paper N.7851,Google Scholar
- Cambridge, MA., Hagedoorn, J. (1993) “Understanding the Rationale of Strategic Technology Partnering: Interorganizational Modes of Cooperation and Sectoral Differences” Strategic Management Journal, Vol.15, pp.3 71–3 85.Google Scholar
- Kline, S. and Rosenberg, N. (1986) “An Overview of Innovation” in Landau, R. and Rosenberg, N. (eds.) The Positive Sum Strategy, National Academy Press, Washington DC.Google Scholar
- Orsenigo L. (1989) The Emergence of Biotechnology, London, Pinter Publishers.Google Scholar
- Pisano, G. (1997) “R&D Performance, Collaborative Arrangements, and the Market for Know-How: A Test of the “Lemons” Hypothesis in Biotechnology”, draft, Harvard Business School.Google Scholar
- Schwartzman, D. (1976) Innovation in the Pharmaceutical Industry, John Hopkins University Press, Baltimore MD.Google Scholar